Clinical Trials Directory

Trials / Completed

CompletedNCT04201899

HYPOPhosphatemia in the Intensive Care: A One-day Point Prevalence Survey

Hypophosphatemia in the ICU - A One-day Point Prevalence Survey

Status
Completed
Phase
Study type
Observational
Enrollment
890 (actual)
Sponsor
Centre Hospitalier Universitaire Vaudois · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The point prevalence survey aims at defining the until now unknown real prevalence of hypophosphatemia (defined as blood phosphate value \< 0.8 mmol/l) in international critical care settings

Detailed description

The survey will be conducted on one single day in each centre (D-day), within a week defined by the project coordinator (International PI). On D-Day, the local investigators will be asked 1. to complete questions aiming at describing their ICU (number of beds, number of patients present on D-Day, type medical/surgical/other, local phosphate reference value, presence of an hypophosphatemia treatment protocol in the ICU and route of phosphate delivery in case of hypophosphatemia) 2. to indicate how many patients had a blood phosphate \<0.08 mmol/l, for each patient with hypophosphatemia, to record the exact lowest value on D-Day, and to record age, number of days in ICU on D-Day, presence (or not) of artificial nutrition and continuous renal replacement therapy, if any phosphate administration is ongoing Data will be recorded in and electronic Case Report Form (e-CRF) in REDCap, and analysed with descriptive statistics No outcome data will be recorded (pure point-prevalence) There is no intervention

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTNo intervention - pure observationPhosphate administration (yes or no)

Timeline

Start date
2020-03-09
Primary completion
2020-07-31
Completion
2020-07-31
First posted
2019-12-17
Last updated
2021-02-02

Locations

4 sites across 3 countries: Estonia, France, Switzerland

Source: ClinicalTrials.gov record NCT04201899. Inclusion in this directory is not an endorsement.